Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

Select Lymphoma Type ∨Select
Lymphoma
Type
Previously untreated Stage III/IV cHLPediatric previously untreated high-risk cHL

cHL post-auto-HSCT consolidation

Relapsed cHLR/R LBCL after ≥2 prior lines of systemic therapyPreviously untreated sALCL or other CD30-expressing PTCLRelapsed pcALCL or CD30-expressing MFRelapsed sALCL
Patient ManagementMOA and CD30 TestingResourcesPatient Assistance
Prescribing InformationPatient InformationIndicationsLoadingPatient Site
ADCETRIS MOA
ADCETRIS: A CD30-directed antibody-drug conjugate1

CD30 is a key biomarker in classical Hodgkin lymphoma and certain peripheral T-cell lymphomas.1

ADCETRIS is part of a class of therapy known as antibody drug conjugates and is designed to target cells expressing CD30.1

Watch ADCETRIS MOA

See how ADCETRIS targets cells expressing CD30.1

Watch videoLoading
Anticancer activity

Nonclinical data suggest that the anticancer activity of ADCETRIS acts via CD30-directed cytotoxicity and antibody-dependent cellular phagocytosis (ADCP). ADCETRIS can also harm normal cells.1

ADCETRIS: A CD30-directed antibody drug conjugate1

The activity of ADCETRIS regardless of CD30 expression may be explainable by several factors and secondary mechanisms including, but not limited to2-7:

  • CD30 immunohistochemistry sensitivity
  • Heterogenous CD30 expression within or between lesions, leading to inaccurate assessment of overall CD30 status
  • Bystander effect when MMAE is released from CD30-positive cells and enters surrounding cells
  • Antibody-dependent cellular phagocytosis
  • Immunogenic cell death
  • Depletion of regulatory T cell (TReg)
Additional mechanisms of action and their potential to complement the direct cytotoxicity of some MMAE-based antibody-drug conjugates are currently under investigation.CD30 BiomarkerTesting CD30 expression quantitatively is critical for diagnosis and treatment decisions1,8
  • CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of systemic anaplastic large cell lymphoma (sALCL) cells, and on Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL). CD30 is variably expressed in other peripheral T-cell lymphomas.1

  • Quantitative testing for CD30 can aid in the differential diagnosis of certain lymphomas1,8
  • Detection of CD30 can help identify patients who may be appropriate candidates for CD30-directed therapy1,8
Explore CD30 expression in cHL subtypes

CD30 is expressed in more than 98% of all cases of cHL.8

Scroll left to view table
cHL SubtypeDescriptionCD30 Expression
Nodular sclerosis cHLCharacterized by collagen bands that surround at least 1 nodule and by HRS cells with lacunar-type morphology994%10
Mixed cellularity cHLCharacterized by classic HRS cells in a diffuse mixed inflammatory background11100%10
Lymphocyte-depleted cHLA diffuse form of cHL rich in HRS cells and/or depleted of non-neoplastic lymphocytes. Histiocytes are usually abundant12100%10
Lymphocyte-rich cHLCharacterized by scattered HRS cells and a nodular or diffuse cellular background consisting of small lymphocytes, with an absence of neutrophils and eosinophils13100%10
Explore CD30 expression in PTCL subtypes

There are approximately 30 different subtypes of CD30-expressing PTCLs14

Scroll left to view table
PTCL SubtypeDescriptionCD30 Expression
Systemic anaplastic large cell lymphoma (sALCL), ALK+/-Large lymphoid cells with abundant cytoplasm and pleomorphic nuclei; expresses CD30 and may or may not express ALK protein15,16100%17
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)Heterogeneous category of nodal and extranodal mature T-cell lymphomas that do not correspond to any specifically defined entities of mature T-cell lymphoma1859%19
Angioimmunoblastic T‑cell lymphoma (AITL)Neoplasm of mature T follicular helper cells characterized by systemic disease and a polymorphous infiltrate involving lymph nodes2076%19
Adult T-cell leukemia lymphoma (ATLL)Mature T-cell neoplasm most often composed of highly pleomorphic lymphoid cells; usually widely disseminated; caused by the human retrovirus HTLV-12136%-56%22-24
Enteropathy-associated T-cell lymphoma (EATL)Neoplasm of intraepithelial T-cells occurring in individuals with celiac disease; exhibits varying degrees of cellular pleomorphism2554%19
Extranodal natural killer (NK)/T-cell lymphomaCharacterized by vascular damage and destruction, prominent necrosis, cytotoxic phenotype, and association with Epstein-Barr virus2652%-75%19,27

ADCETRIS+CHP is approved for any level of CD30 expression.
Make sure no appropriate patient is missed.1

ALK = anaplastic lymphoma kinase; HTLV-1 = human T-lymphotropic virus type 1.

CD30 Testing in PTCLsCD30 testing is critical for identifying patients with PTCLs eligible for ADCETRIS
  • Expression of CD30 is reported inconsistently in pathology results (often binary [eg, positive/negative])28,29
  • Eligible patients may be overlooked for treatment if the percentage expression is not reported1,28,29
CD30 expression should be reported as a percentage for all PTCL subtypesPlus sign icon inside a circle % CD30

Percentage stated
Any CD30 expression (%) renders patients eligible for ADCETRIS1

Minus sign icon inside a circle Negative CD30

Binary results
Qualitative reporting may miss patients with CD30 expression who qualify for ADCETRIS1,28,29

Ask pathologists to consistently report CD30 expression as a percentage for all PTCL subtypesResources for your patients and practice Find Useful Resources LoadingAPC = antigen-presenting cell; FcyR = fragment crystallizable gamma receptor; MHC = major histocompatibility complex; MOA = mechanism of action; TCR = T-cell receptor.References:ADCETRIS Prescribing Information. Bothell, WA: Seagen Inc.Gru AA, Lim MS, Dogan A, et al. Best practices in CD30 immunohistochemistry testing, interpretation, and reporting: an expert panel consensus. Arch Pathol Lab Med. 2023;147(1):79-86.Jagadeesh D, Horwitz S, Bartlett NL, et al. Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma. Oncologist. 2022;27(10):864-873.Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888-897.Heiser RA, Cao AT, Zeng W, et al. Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity. Mol Cancer Ther. 2024;23(1):68-83.Heiser RA, Grogan BM, Manlove LS, Gardai SJ. CD30+ T regulatory cells, but not CD30+ CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo (Abstract 1789). Cancer Res. 2018;78(13 Suppl):1789.Grogan B, James R, Ulrich M, Gardai S, Heiser R. 696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo. J Immunother Cancer. 2020;8(Suppl 3). doi:10.1136/jitc-2020-SITC2020.0696Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol. 2002;55:162-176.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Nodular sclerosis classic Hodgkin lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5372/Konkay K, Paul TR, Uppin SG, Rao DR. Hodgkin lymphoma: a clinicopathological and immunophenotypic study. Indian J Med Paediatr Oncol. 2016;37(1):59-65.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Mixed cellularity classic Hodgkin lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5342/National Cancer Institute Surveillance, Epidemiology, and End Results Program. Lymphocyte-depleted classic Hodgkin lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd533f/National Cancer Institute Surveillance, Epidemiology, and End Results Program. Lymphocyte-rich classic Hodgkin lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5348/Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Anaplastic large cell lymphoma, ALK-positive. Accessed February 2, 2026. https:// seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd52fd/National Cancer Institute. Anaplastic large cell lymphoma, ALK-negative. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/5a7dd4531ef55751804d309f/Delsol G, Falini B, Müller-Hermelink HK, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:312-316.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Peripheral T-cell lymphoma, NOS. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd52e8/Federico M, Bellei M, Luminari S, et al. CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. J Clin Oncol. 2015;33:8552.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Angioimmunoblastic T-cell lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd52dc/National Cancer Institute Surveillance, Epidemiology, and End Results Program. Adult T-cell leukemia/lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf59e3e27c3994bd544d/Campuzano-Zuluaga G, Pimentel A, Chapman-Fredricks JR, Ramos JC. Differential CD30 expression in adult T-cell leukemia-lymphoma subtypes. Retrovirology. 2014;11:P129.Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983-2986.Lunning MA, Chiu A, Feldstein JT, et al. CD30 is a potential therapeutic target in patients with HTLV-1 associated adult T-cell leukemia/lymphoma presenting outside of Japan. Blood. 2012;120:2706.National Cancer Institute Surveillance, Epidemiology, and End Results Program. Enteropathy-associated T-cell lymphoma. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/National Cancer Institute Surveillance, Epidemiology, and End Results Program. Extranodal NK-/T-cell lymphoma, nasal type. Accessed February 2, 2026. https://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd530f/Pongpruttipan T, Kummalue T, Bedavanija A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand. Diagn Pathol. 2011;6:79.Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402-3408.Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394-1402.
Available on this page:

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1T-USA-1084
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Indications

ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL

  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Previously untreated high risk cHL

  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

cHL post-auto-HSCT consolidation

  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Relapsed cHL

  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Previously untreated sALCL or other CD30-expressing PTCL

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Relapsed sALCL

  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

Relapsed pcALCL or CD30-expressing MF

  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Relapsed and Refractory Large B-Cell Lymphoma (LBCL)

  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.

Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

CONTRAINDICATION

Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN):
ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.

Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.

Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1  week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.

Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult  patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays,  reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including  fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.

Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.

Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.

Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.

Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.

PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.

Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and  dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.

Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.

Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.

Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.

Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS  treatment and for 4 months after the last dose of ADCETRIS.

ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are  peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased  neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST. 

The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect  the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.

USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.IndicationsADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL
  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Previously untreated high risk cHL
  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
cHL post-auto-HSCT consolidation
  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Relapsed cHL
  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
Previously untreated sALCL or other CD30-expressing PTCL
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Relapsed sALCL
  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.
Relapsed pcALCL or CD30-expressing MF
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.